2-mercaptothiazol-4-yl-acetamide | 194929-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-mercaptothiazol-4-yl-acetamide
• 英文别名: 2-mercapto-4-thiazole acetamide；2-(2-sulfanylidene-3H-1,3-thiazol-4-yl)acetamide
• CAS: 194929-80-1
• 化学式: C₅H₆N₂OS₂
• 分子量: 174.247
• InChiKey: AXLODPKGGNOBAS-UHFFFAOYSA-N

物化性质

• 沸点：
  394.4±44.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-mercaptothiazol-4-yl-acetamide 在 potassium tert-butylate 、 苯甲醚 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 为溶剂， 生成 (6R,7R)-3-(4-Carbamoylmethyl-thiazol-2-ylsulfanyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879

  摘要：

  The synthesis, therapeutic efficacy against H. pylori, and preliminary safety of the novel cephem. derivative, FR193879 (8a) are described. Compound 8a having a (4-carbamoylmethylthiazol-2-yl)thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have good safety showing a nontoxic dose of >100 mg/kg in dogs in a 4-week repeat dose toxicity study and extremely potent therapeutic efficacy against H. pylori, showing 30 times superior activity compared to AMPC, and did not display cross-resistance with CAM or MNZ. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.068
• 作为产物：
  描述：

  2,3-二氢-2-硫代-4-噻唑乙酸乙酯 在 ammonium hydroxide 、 氯化铵 作用下， 生成 2-mercaptothiazol-4-yl-acetamide
  参考文献：
  名称：

  Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879

  摘要：

  The synthesis, therapeutic efficacy against H. pylori, and preliminary safety of the novel cephem. derivative, FR193879 (8a) are described. Compound 8a having a (4-carbamoylmethylthiazol-2-yl)thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have good safety showing a nontoxic dose of >100 mg/kg in dogs in a 4-week repeat dose toxicity study and extremely potent therapeutic efficacy against H. pylori, showing 30 times superior activity compared to AMPC, and did not display cross-resistance with CAM or MNZ. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.068

文献信息

• Cephem compounds and pharmaceutical use thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06150351A1

  公开（公告）日：2000-11-21

  This invention relates to new cephem compound represented by the following general formula (I): ##STR1## wherein each symbol is as defined in the specification or a salt thereof, which has antimicrobial activity against Helicobacter pylori, and are useful as anti-Helicobacter pylori agents, anti-gastritis agents, anti-ulcer agents and anti-cancer agents.

  本发明涉及一种由以下一般式（I）表示的新头孢素化合物：其中每个符号如规范中定义或其盐，具有抗幽门螺杆菌活性，并可用作抗幽门螺杆菌药物、抗胃炎药物、抗溃疡药物和抗癌药物。